FDA
-
-
-
-
-
-
-
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
-
-
-
-
-
-
-
Regeneron agrees to lower drug prices, offer gene therapy for free
-
-
-
-
-
-
-
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
-
-
-
-
-
-
-
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $975 at Guggenheim
-
-
-
-
-
-
-
Regeneron and Tessera partner on gene editing therapy for rare disease
-
323,999 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

